Sugimoto Hitoshi, Miura Tomiyuki, Kawamura Yudai, Aburatani Tomoki, Hanaoka Marie, Ogo Taichi, Hoshino Naoaki, Nishioka Yoshinobu, Kawano Tatsuyuki
Dept. of Surgery, Soka Municipal Hospital.
Gan To Kagaku Ryoho. 2019 Dec;46(13):2246-2248.
A 50-year-old woman had noted a mass in her right breast 2 years ago but did not consult a hospital. She consulted our hospital because the mass increased in size and also reddened. The tumor measured 10 cm in diameter and was palpable in the whole right breast. A core needle biopsy was performed, and invasive ductal carcinoma was diagnosed. CT showed multiple lung and liver metastases and bone scintigraphy showed bone metastases in a rib. Because the lung and liver metastases were life-threatening, paclitaxel(PTX)chemotherapy was administered weekly. Biomarkers analysis revealed ER(+), PgR(+), HER2(2+), HER2 FISH 1.27, Ki-67 30%, and bevacizumab (Bev) was added from 2 courses. After 4 courses of chemotherapy, the multiple lung and liver metastases were found to be significantly reduced on CT. Toxicities included alopecia, hypertension, and proteinuria. At this time, 3 years after the treatment started, PTX plus Bev combination therapy was also administered.
一名50岁女性两年前发现右乳有一肿块，但未就医。因肿块增大且变红，她前来我院就诊。肿瘤直径达10厘米，整个右乳均可触及。进行了粗针穿刺活检，诊断为浸润性导管癌。CT显示肺部和肝脏有多处转移，骨扫描显示一根肋骨有骨转移。由于肺部和肝脏转移危及生命，每周给予紫杉醇（PTX）化疗。生物标志物分析显示雌激素受体（ER）阳性、孕激素受体（PgR）阳性、人表皮生长因子受体2（HER2）（2+）、HER2荧光原位杂交（FISH）为1.27、Ki-67为30%，从第2个疗程开始加用贝伐单抗（Bev）。化疗4个疗程后，CT显示肺部和肝脏的多处转移明显减少。毒性反应包括脱发、高血压和蛋白尿。此时，治疗开始3年后，也给予了PTX加Bev联合治疗。
